




PHARMACEUTICAL 2019

AILERON THERAPEUTICS INC
Rank 251 of 363





PHARMACEUTICAL 2019

AILERON THERAPEUTICS INC Rank 251 of 363

The relative strengths and weaknesses of AILERON THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AILERON THERAPEUTICS INC compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 53% points. The greatest weakness of AILERON THERAPEUTICS INC is the variable Net Income, reducing the Economic Capital Ratio by 73% points.

The company's Economic Capital Ratio, given in the ranking table, is 11%, being 26% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	21,775
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,370
Liabilities, Non-Current	0
Other Assets	1,247
Other Compr. Net Income	28
Other Expenses	0
Other Liabilities	5,342
Other Net Income	355
Other Revenues	0
Property and Equipment	7,290
Research and Development	18,448
Selling, General and Administrative Expense	13,454

Output Variable	Value in 1000 USD
Assets	30,312
Liabilities	10,712
Expenses	31,902
Revenues	0
Stockholders Equity	19,600
Net Income	-31,547
Comprehensive Net Income	-31,533
Economic Capital Ratio	11%